AstraZeneca Pharma India is planning to divest its 64-acre manufacturing facility in Bengaluru, with the transaction expected to be valued at around ₹3,400 crore. The move is part of the company’s broader global strategy to optimise its manufacturing footprint and unlock value from non-core assets.
Located in North Bengaluru, the land parcel is considered highly valuable due to its size, connectivity, and proximity to key growth corridors. The deal is estimated at over ₹50 crore per acre, reflecting the sharp appreciation in land prices across the city. Large, contiguous land parcels within urban limits are increasingly scarce, making this asset particularly attractive to both developers and corporates.
Key Highlights
Transaction Value: ~₹3,400 crore
Land Size: 64 acres in North Bengaluru
Valuation: Over ₹50 crore per acre
Strategic Intent: Global portfolio optimisation by AstraZeneca
Buyer Interest: Strong interest from leading developers and corporates
End Use Potential: Residential, commercial, or mixed-use redevelopment
Buyer Interest and Development Potential
The proposed divestment has drawn interest from major players such as Sattva Group, RMZ Corp and Aurobindo Pharma. For developers, the scale of the land presents a rare opportunity to undertake large, master-planned developments within city limits.
Given its location, the site is well-suited for premium residential projects, Grade A office spaces, or integrated mixed-use developments. With Bengaluru continuing to attract global companies and talent, demand for high-quality real estate across segments remains strong.
Strategic Rationale
The divestment aligns with AstraZeneca’s ongoing efforts to streamline operations and focus on core business areas. Globally, companies are increasingly adopting asset-light models, reducing ownership of large manufacturing facilities and instead leveraging more flexible supply chain structures.
By monetising this asset, AstraZeneca can redeploy capital into innovation, research, and growth markets, while maintaining its business presence in India.
Market Implications
This transaction highlights a broader trend of corporates unlocking value from surplus land amid rising real estate prices in metro cities. Bengaluru, in particular, has seen strong land value appreciation driven by its technology ecosystem and sustained demand for residential and commercial spaces.
Large land deals of this scale are rare and often act as catalysts for further development in surrounding areas. The eventual redevelopment of this site could significantly enhance the micro-market, driving new investments and infrastructure growth.
Conclusion
The proposed ₹3,400 crore sale of AstraZeneca India’s Bengaluru facility underscores the growing strategic importance of land monetisation for corporates, as well as the continued appetite among developers for high-quality urban land parcels. As the deal progresses, it is likely to set a benchmark for future transactions in the city’s real estate market.
.png)